Patents Assigned to Mylan Laboratories Ltd.
-
Publication number: 20180282351Abstract: The present disclosure provides amorphous ixazomib citrate and processes for the preparation thereof. Crystalline form M1, form M2, form M3, and form M4 of ixazomib citrate are also disclosed. The present disclosure also encompasses processes for the preparation of those crystalline forms.Type: ApplicationFiled: September 15, 2016Publication date: October 4, 2018Applicant: Mylan Laboratories LtdInventors: Vinayak GORE, Rajesh JOSHI, Anil TRIPATHI, Madhukar PATIL, Ramakoteswara Rao JETTI, Anjaneyaraju INDUKURI, Amit SINGH, Soumyajit GHOSH
-
Publication number: 20180244693Abstract: Processes for the preparation of dolutegravir and pharmaceutically acceptable salts utilizing alkenylamine are disclosed. Intermediates in those synthetic schemes are also disclosed.Type: ApplicationFiled: February 5, 2016Publication date: August 30, 2018Applicant: Mylan Laboratories Ltd.Inventors: Sivaram Prasad VELLANKI, Madumurthy NADELLA, Mitali BHALME, Revathi Srinivas RAMABHOTLA, Venkata Siva Reddy ARUMALLA, Raveendra Babu KILARU
-
Patent number: 9815789Abstract: The present disclosure provides novel crystalline forms of cabozantinib (S)-malate, designated as form-M1, M2, M3 and M4 and novel crystalline forms of cabozantinib free base, form-M1, M2 and M3 and methods of their production. The present disclosure also provides processes for the preparation of crystalline cabozantinib (S)-malate form N-1.Type: GrantFiled: May 22, 2015Date of Patent: November 14, 2017Assignee: Mylan Laboratories, Ltd.Inventors: Ramakoteswara Rao Jetti, Anjaneyaraju Indukuri, Dnyandeo Punde, Chandersingh Bohra, Mahesh Kumar Gadakar, Vinayak Gore
-
Publication number: 20170319539Abstract: The present disclosure relates to solid dispersion of amorphous empagliflozin and its process thereof.Type: ApplicationFiled: October 1, 2015Publication date: November 9, 2017Applicant: Mylan Laboratories LTD.Inventors: Ramakoteswara Rao Jetti, Aggi Ramireddy Bommareddy, Amit Singh, Vijaya Krishna Ravi, Subramanyam Dandala
-
Patent number: 9796750Abstract: The present disclosure relates to an improved process for the preparation of fluticasone propionate.Type: GrantFiled: February 5, 2015Date of Patent: October 24, 2017Assignee: Mylan Laboratories Ltd.Inventors: Sakharam Jadhav, Chandersingh Bohara, Ghanshyam Wagh, Vinayak Govind Gore, Maheshkumar Gadakar
-
Publication number: 20170174719Abstract: The present disclosure relates to an improved process for the purification of fluticasone propionate by: a) dissolving fluticasone propionate in a ketone solvent to produce a mixture, b) heating the mixture slowly for 1-2 hours to get a clear solution, c) adding water to the step (b) solution at 50-60° C., d) cooling to ?5° C. to 10° C., and e) isolating fluticasone propionate.Type: ApplicationFiled: February 5, 2015Publication date: June 22, 2017Applicant: Mylan Laboratories Ltd.Inventors: Sakharam Jadhav, Chandersingh Bohara, Ghanshyam Wagh, Vinayak Govind Gore, Maheshkumar Gadakar
-
Patent number: 9630909Abstract: Described herein are processes for the preparation of nepafenac and related intermediates, particularly wherein 2-aminobenzophenone is treated with a 2-(alkylthio)acetamide in the presence of sulfuryl chloride to afford a 2-(2-amino-3-benzoyl-phenyl)-2-(alkylthio)acetamide, which upon reduction affords nepafenac. Described herein are also processes for the purification of nepafenac, particularly for the removal of structurally similar impurities.Type: GrantFiled: June 26, 2014Date of Patent: April 25, 2017Assignee: Mylan Laboratories LtdInventors: Sebastian Sonny, Rao Jagadeeshwar, Srinivas Rao Mannava, Suresh Reddy Sabbella
-
Patent number: 9273333Abstract: The present invention relates to an improved process for the preparation of compound of Formula-II, which is an intermediate in the preparation of HMG-CoA reductase inhibitors. wherein X is hydrogen or hydroxy protecting group and R1 is carboxyl protecting group.Type: GrantFiled: May 28, 2014Date of Patent: March 1, 2016Assignee: Mylan Laboratories LTDInventors: Michiel Christian Alexander Van Vliet, Willem Robert Klaas Schoevaart, Madhuresh Kumar Sethi, Sanjay Mahajan, Bhairaiah Mara
-
Publication number: 20150299200Abstract: The present invention relates to a process for preparing Linagliptin by purifying the intermediate compounds converting the purified intermediates into Linagliptin. The present invention also relates to the preparation of an amorphous Linagliptin.Type: ApplicationFiled: December 16, 2013Publication date: October 22, 2015Applicant: MYLAN LABORATORIES LTDInventors: Bhausaheb CHAVHAN, Jebaraj RATHINAPANDIAN, Shiva Kumar CHANDUPTLA, Nagaraji GHANDA
-
Patent number: 9145365Abstract: The present invention relates to an improved process for the preparation of Roflumilast. The present invention also relates to crystalline Form-I of Roflumilast.Type: GrantFiled: May 8, 2014Date of Patent: September 29, 2015Assignee: Mylan Laboratories Ltd.Inventors: Priyesh Vijaykar, Dattatrey Kokane, Sushant Gharat, Dhananjay Shinde, Manojkumar Bindu, Vinayak Gore
-
Patent number: 8993786Abstract: The main object of the present invention relates to a novel crystalline form of Fosemprenavir Calcium designated as Form A. Another object of the present invention relates to a process for the preparation of Crystalline Form A of Fosemprenavir Calcium. Yet another object of the present invention relates to crystalline Forma A of Fosemprenavir Calcium characterized by a PXRD diffraction having reflections at about 3.1±0.2, 4.4±0.2, 5.0±0.2, 6.3±0.2, 7.4±0.2, 8.0±0.2, 2?.Type: GrantFiled: February 9, 2012Date of Patent: March 31, 2015Assignee: Mylan Laboratories Ltd.Inventors: Ramakoteswara Rao Jetti, Neelima Bhagavatula, Asha Rani Gorantla
-
Patent number: 8974824Abstract: The present invention discloses stable, solid oral pharmaceutical composition comprising Lanthanum carbonate having more than 6 molecules of water per molecule of lanthanum carbonate and pharmaceutically acceptable carriers or diluents, wherein said carrier or diluent excludes monosaccharide/s or disaccharide/s, such that the composition has comparable in-vitro dissolution profile similar to that of FOSRENOL®. Also disclosed is a wet granulation process for making the same.Type: GrantFiled: March 24, 2009Date of Patent: March 10, 2015Assignee: Mylan Laboratories Ltd.Inventors: Nagaraj Amminabavi, Indu Bhushan, Satish Kumar Jain, Subhash Gore, Gnanadeva Chalapathy Gudipati, Balakrishnan Chinnu, Subramanian Iyer, Manoj P Kumar, Rajesh S Gupta
-
Publication number: 20150011793Abstract: The present invention relates to an improved process for the preparation of pure compound of Formula-II, which is an intermediate in the preparation of Aliskiren and further conversion of compound of Formula-II into Aliskiren or its pharmaceutically acceptable salts.Type: ApplicationFiled: February 15, 2013Publication date: January 8, 2015Applicant: MYLAN LABORATORIES LTDInventors: Shankar Rama, Seshadri Rao Manukonda, Srinivasa Rao Dasari
-
Publication number: 20140299176Abstract: Apparatus for the industrial wiring and final testing of photovoltaic concentrator modules, consisting of a module frame, a lens disc, a sensor carrier disc and an electrical line routing arrangement, comprising the following features: a) a laser contact-making device for the contactless connection of connecting lines between the individual sensors and of connecting elements and of collective contact plates, wherein the line routing arrangement on the sensor carrier disc as basic structure has in each case 5 CPV sensors connected in parallel, and these parallel circuits are connected in series, b) a device for testing electrical properties, wherein a specific voltage is applied to CPV sensors themselves, and the light emitted by them via the lenses is detected and assessed, c) a device for testing tightness of finished concentrator modules, wherein compressed air is applied to the modules in the interior and the emission of compressed air is checked.Type: ApplicationFiled: December 7, 2012Publication date: October 9, 2014Applicant: Mylan Laboratories LTD.Inventor: Eckart Gerster
-
Publication number: 20140283486Abstract: The present invention relates to polymorphic forms of Febuxostat and processes for the preparation of polymorphic forms of Febuxostat.Type: ApplicationFiled: May 15, 2014Publication date: September 25, 2014Applicant: MYLAN LABORATORIES LTDInventors: Ramakoteswara Rao JETTI, Balakrishna Reddy Bhogala, Satish Beeravelli
-
Publication number: 20140275551Abstract: The present invention relates to an improved process for the preparation of Roflumilast. The present invention also relates to crystalline Form-I of Roflumilast.Type: ApplicationFiled: May 8, 2014Publication date: September 18, 2014Applicant: MYLAN LABORATORIES LTD.Inventors: Priyesh VIJAYKAR, Dattatrey Kokane, Sushant Gharat, Dhananjay Shinde, Manojkumar Bindu, Vinayak Gore
-
Publication number: 20130317236Abstract: The main object of the present invention relates to novel crystalline form of Fosamprenavir Calcium designated as Form A. Another object of the present invention relates to a process for the preparation of Crystalline Form A of Fosamprenavir Calcium. Yet another object of the present invention relates to crystalline Form A of Fosamprenavir Calcium characterized by an PXRD diffraction having reflections at about 3.1±0.2, 4.4±0.2, 5.0±0.2, 6.3±0.2, 7.4±0.2, 8.0±0.2, 28.Type: ApplicationFiled: February 9, 2012Publication date: November 28, 2013Applicant: MYLAN LABORATORIES LTD.Inventors: Ramakoteswara Rao Jetti, Neelima Bhagavatula, Asha Rani Gorantla
-
Publication number: 20130244297Abstract: The present invention relates to a novel process for the preparation of (3R, 3aS, 6aR)-hexahydrofuro[2, 3-b]furan-3-ol of formula I by reacting a compound of formula VII with the compound of formula R2-OH in the presence of haloginating agent to obtain a compound of formula VI and treating a compound of formula VI with dehaloginating agent to obtain a compound of formula V by reducing a compound of formula V, followed by cylization to obtain compound of formula IV and separating the enantiomer and diastereomers from compound of formula IV to yield a compound of formula I. Compound of formula I is useful as an intermediate in the preparation of protease inhibitors, in particular broad spectrum HIV protease inhibitors, the present invention also relates to process for the preparation of Darunavir from (3R, 3aS, 6aR)-hexahydrofuro[2, 3-b]furan-3-ol.Type: ApplicationFiled: July 14, 2011Publication date: September 19, 2013Applicant: Mylan Laboratories Ltd.Inventors: Siva Rama Prasad Vellenki, Arabinda Sahu, Nitin Ashok Shimpi, Anil Ponnuru, Satish Babu Kothari
-
Patent number: 8367080Abstract: The invention discloses a formulation prepared by granulating at least one anti-retro viral drug and at least one pharmaceutically acceptable additive, using an organic solvent; milling the product; finally processing the milled product to form tablets or capsules.Type: GrantFiled: June 10, 2011Date of Patent: February 5, 2013Assignee: Mylan Laboratories Ltd.Inventors: Kiran Kumar Narsaiah Velaveni, Sanjay Deshraj Verma, Akhilesh Ashok Dixit, Abhijit Mukund Deshmukh, Sanjeev Meharchand Sethi
-
Patent number: 8309723Abstract: Present invention relates to an improved process for the preparation of Zopiclone and its enantiomerically enriched isomer (Eszopiclone). 6-(5-Chloropyridin-2-yl)-5-hydroxy-7-oxo-5,6-dihydropyrrolo[3,4-b]pyrazine is reacted with 1-chloro-carbonyl-4-methylpiperazine in the presence of alkali earth metal carbonates, hydroxides or oxides in a solvent medium to give Zopiclone. It is reacted with optically active acid in a mixture of water and water miscible organic solvent followed by work up to give Eszopiclone. The present invention also relates to process for the conversion of (R) or (S) Zopiclone to 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5,6-dihydro-pyrrolo-[3,4-b]-pyrazine of the intermediate which can be converted to racemic Zopiclone.Type: GrantFiled: April 10, 2008Date of Patent: November 13, 2012Assignee: Mylan Laboratories Ltd.Inventors: Om Dutt Tyagi, Tushar Kumar Srivastava, Vellanki Siva Ram Prasad, Dnyandev Ragho Rane, Bandi Naga Durga Rao, Daggula Srinivas Reddy